Schulman, Kevin A., Suresh Balu, and Shelby D. Reed. “Specialty Pharmaceuticals for Hyperlipidemia–Impact on Insurance Premiums.” The New England Journal of Medicine 373, no. 17 (October 22, 2015): 1591–93. https://doi.org/10.1056/NEJMp1509863.
The approval of PCSK9 inhibitors with broad indications sets the practice of cardiology on a collision course with specialty pharmaceutical pricing models that were previously reserved for drugs that benefited relatively limited patient populations.